<p>Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Catherine Miller, PharmD, global medical affairs lead for hereditary angioedema (HAE) at Intellia Therapeutics, on an experimental gene editing therapy known as lonvo-Z.</p>

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Catherine Miller, PharmD, global medical affairs lead for hereditary angioedema (HAE) at Intellia Therapeutics, on an experimental gene editing therapy known as lonvo-Z.

192: An Interview With Catherine Miller, PharmD, of Intellia Therapeutics on an Experimental Gene Editing Therapy for HAE

Rare Disease Advisor's Rare Care Podcast features exclusive interviews with experts and stakeholders from the rare disease community.

Share 192: An Interview With Catherine Miller, PharmD, of Intellia Therapeutics on an Experimental Gene Editing Therapy for HAE

Sign up to save your podcasts

192: An Interview With Catherine Miller, PharmD, of Intellia Therapeutics on an Experimental Gene Editing Therapy for HAE

192: An Interview With Catherine Miller, PharmD, of Intellia Therapeutics on an Experimental Gene Editing Therapy for HAE